期刊文献+

趋化因子CCL5在涎腺腺样囊性癌患者肿瘤组织和血清中的表达及临床意义 被引量:4

Expression of Chemokine CCL5 in Tumor Tissue and Serum of Patients with Salivary Adenoid Cystic Carcinoma and Its Clinical Significance
下载PDF
导出
摘要 目的 研究趋化因子CCL5在涎腺腺样囊性癌(salivaryadenoid cystic carcinoma,SACC)患者肿瘤组织和血清中的表达及临床意义。方法 收集SACC患者76例术前血清样本、手术中肿瘤组织和癌旁腮腺组织病理切片,32例体检健康对照者血清样品。应用免疫组织化学法检测CCL5及其受体CCR5蛋白在SACC肿瘤和癌旁组织中的表达,ELISA法检测血清CCL5水平。结果 SACC肿瘤组织中CCL5和CCR5表达水平明显高于癌旁组织,且差异均具有统计学意义(P<0.001)。观察组血清中CCL5的表达量为(8.43±1.36)ng/ml,显著高于对照组的(1.11±0.78)ng/ml(P<0.001)。不同肿瘤发生部位的患者血清CCL5水平间差异无统计学意义(P>0.05);不同组织学分型、淋巴结转移情况、肿瘤TMN分期的患者间血清CCL5水平差异具有统计学意义(P<0.05)。血清CCL5水平与肿瘤组织中CCL5蛋白表达呈正相关(γ=0.742,P<0.001),与肿瘤细胞中CCR5蛋白表达亦呈正相关(γ=0.799,P<0.001)。结论 趋化因子CCL5的异常表达可能在SACC的发生与发展过程中起重要作用,并有可能作为临床上SACC早期监测指标。 Objective To study the expression and clinical significance of chemokine CCL5 in tumor tissue and serum of salivary adenoid cystic carcinoma. Methods The serum samples of 76 patients with SACCOur hospital,were collected.Detection of CCL5 and its receptor CCR5 protein in SACC tumor and paracancerous tumor by immunohistochemical method The level of serum CCL5 was detected by Elisa. Results The expression levels of CCL5 and CCR5 in the tumor tissues were significantly higher than those of the paracancerous tissues ( P <0.001).The expression of CCL5 in serum of the observation group was significantly higher than that of the control group (8.43±1.36)ng/ml vs (1.11±0.78)ng/ml vs (1.11±0.78)ng/ml, P <0.05.There was no significant difference in serum CCL5 levels among patients with different tumor sites ( P >0.05).There was significant difference in serum CCL5 level between patients with TMN staging ( P <0.05).The level of serum CCL5 was positively correlated with the expression of CCL5 protein in tumor tissues ( P <0.742, P <0.05).The expression of CCR5 protein was positively correlated with the expression of CCR5 protein in tumor cells ( P <0.05, P <0.05, P <0.05). Conclusion The abnormal expression of chemokine CCL5 may play an important role in the occurrence and development of SACC,and may be used as an early clinical monitoring index for SACC.
作者 达成利 帕拉提·艾斯卡 比力克孜·玉素甫 DA Chengli;Palati·aisika;Bilikezi·yushufu(First People's Hospital,Kashi,844000)
出处 《实用癌症杂志》 2019年第6期891-894,共4页 The Practical Journal of Cancer
关键词 趋化因子 CCL5 腺样囊性癌 Chemokine CCL5 Adenoid cystic carcinoma
  • 相关文献

参考文献12

二级参考文献137

  • 1芦杨,齐鸿亮.MMP-2和MVD在腺样囊性癌中的表达及临床意义[J].中国实用口腔科杂志,2009,2(7):415-417. 被引量:5
  • 2刘文胜,唐平章,祁永发,高黎,李正江.腭部腺样囊性癌的诊治及预后因素的探讨[J].中华肿瘤杂志,2004,26(8):485-489. 被引量:27
  • 3郑刚,郭传瑸,俞光岩,黄敏娴,彭歆,黄俊.腺样囊性癌患者生存预测模型的建立[J].中华口腔医学杂志,2006,41(6):350-353. 被引量:13
  • 4姚晓莉,童鹤翔,涂毅,姚峰,王卫星,孙圣荣.CCL5及其受体在乳腺癌组织中的表达及其意义[J].中华实验外科杂志,2007,24(5):590-592. 被引量:15
  • 5GLADUE R P,COLE S H,ROACH M L,et al.The human specific CCR1 antagonis CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice[J].J Immunol,2006,176(5):3141-3148.
  • 6POTTEAUX S.Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice[J].Mol Med,2005,11(1-12):16-20.
  • 7ZERNECKE A,LIEHN E A,GAO J L,et al.Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice:involvement of IL-10[J].Blood,2006,107(11):4240-4243.
  • 8BRAUNERSREUTHER V,ZERNECKE A,ARNAUD C,et al.Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice[J].Arterioscler Thromb Vasc Biol,2007,27(2):373-379.
  • 9SCHENK S,MAL N,FINAN A,et al.Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor[J].Stem Cells,2007,25(1):245-251.
  • 10FILIPPATOS G,PARISSIS J T,ADAMOPOULOS S,et al.Chemokines in cardiovascular remodeling:clinical and therapeutic implications[J].Curr Mol Med,2003,3(2):139-147.

共引文献64

同被引文献34

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部